SNAP-25 Reporter Constructs for In Vitro BoNT Potency Testing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing methods for determining the batch potency of botulinum neurotoxins (BoNT) rely on animal-based assays like the mouse LD50 bioassay, which are costly, lack specificity, and face ethical concerns, necessitating a more reliable and reproducible alternative.
Innovation Solution
Development of SNAP-25 reporter constructs comprising various tags or domains, such as MYC, FLAG, and DIABLO, to quantify BoNT activity in vitro through cleavage assays using ELISA or flow cytometry.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If animal-based assays (mouse LD50 bioassay) are used to determine BoNT potency, then measurement precision can be achieved, but operational cost increases and animal testing is required
Solution Approach 1:
The patent creates a simplified copy of the BoNT-SNAP25 interaction system using a reporter construct that mimics the natural substrate. Instead of using actual animal models, the invention uses a engineered protein construct with cleavable SNAP-25 domain followed by a reporter domain, allowing potency measurement through detection of cleavage products via ELISA or flow cytometry, thus reducing operational cost while maintaining measurement precision
Solution Approach 2:
The patent introduces an intermediary detection system using antibodies or fluorescent tags that bind to the reporter domain. This intermediary allows indirect measurement of BoNT activity through the cleavage of the reporter construct, eliminating the need for direct animal testing while providing quantifiable potency data
2Measurement precision
If animal-based assays are used to determine BoNT potency, then measurement precision can be achieved, but the assay lacks specificity for different BoNT serotypes
Solution Approach 1:
The patent applies local quality by incorporating specific recognition elements (antibodies or fluorescent tags) that bind to particular domains of the reporter construct. This allows the assay to be tailored to detect specific BoNT serotypes or cleavage patterns, providing serotype-specific measurement precision while maintaining the overall simplicity of the in vitro system
3Measurement precision
If animal-based assays are used to determine BoNT potency, then potency data can be obtained, but the method is complex and requires large animal groups
Solution Approach 1:
The patent segments the complex animal-based assay into discrete in vitro components: the reporter construct with SNAP-25 domain and reporter domain, the BoNT sample, and the detection reagents. This segmentation allows the assay to be performed in simplified in vitro conditions using smaller sample amounts and eliminating the need for large animal groups, reducing overall complexity while maintaining measurement precision
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Provides a validated, reproducible method for determining BoNT potency without animal testing, offering high specificity and reducing operational costs while maintaining accuracy.
Implementation Method 1
Botulinum toxin (i.e., botulinum neurotoxin or 'BoNT') is a neurotoxic protein produced by the bacterium Clostridium botulinum and related species. BoNT prevents the release of the neurotransmitter acetylcholine from axon endings at the neuromuscular junction
Implementation Method 2
the DIABLO domain comprises any one of SEQ ID NOs: 7, 8, or 14
Data Source
AI summary
The present disclosure relates generally to peptide reporter constructs of SNAP-25, which are useful in determining the activity of botulinum toxins, and methods of using the same.